Treatment of Anaerobic Infections

General Principles

1. Appropriate antimicrobial therapy - targeted to the likely or confirmed anaerobes
2. Surgical intervention - drainage of abscesses, decompression of closed-space infections, relief of obstructions, debridement of necrotic tissue
3. Duration - generally longer than for aerobic infections; may require 6-8 weeks, but can be shortened with adequate surgical drainage

• Goldman-Cecil Medicine, p. 3077

Key Antimicrobial Agents

1. Metronidazole (Drug of Choice for Most Anaerobic Infections)

• Mechanism: Selectively taken up by anaerobes; nonenzymatically reduced by ferredoxin, generating metabolites that intercalate into bacterial DNA, forming unstable molecules. This reduction occurs only in anaerobic cells, sparing human cells and aerobes.
• Spectrum: Bacteroides fragilis group, Clostridium spp., Fusobacterium spp., most obligate anaerobes. Does NOT cover aerobes or microaerophilic streptococci.
• PK: Excellent oral bioavailability; CSF/brain penetration equal to serum levels (useful for brain abscess); metabolized hepatically (dose-adjust in liver failure).
• Dosage: 500 mg PO/IV TID (or 30 mg/kg/day); single 2 g dose for bacterial vaginosis/trichomonas.
• Uses: Intra-abdominal infections (+ aerobic coverage), pelvic infections, brain abscess, anaerobic lung infections, C. difficile (IV combined with oral vancomycin in fulminant disease only - no longer first-line alone).
• Adverse effects: Nausea, diarrhea, stomatitis, peripheral neuropathy with prolonged use. The disulfiram-alcohol interaction previously attributed to it is not well-supported by re-evaluation of evidence.
• Katzung's Basic and Clinical Pharmacology, 16th Ed., p. 1393

2. Beta-Lactam/Beta-Lactamase Inhibitor Combinations (Broad-Spectrum, Often First Choice for Mixed Infections)

3. Carbapenems (Broadest Coverage, Reserved for Resistant/Severe Infections)

• Imipenem, meropenem, doripenem, ertapenem all have excellent anaerobic activity
• Retain activity against B. fragilis group when other agents have failed
• One RCT showed ceftolozane/tazobactam + metronidazole was equivalent to meropenem for complicated intra-abdominal infections including MDR pathogens

4. Clindamycin

• Active against gram-positive anaerobes (Peptostreptococcus, Clostridium spp.) and many gram-negative anaerobes
• Resistance is increasing in B. fragilis group - no longer reliable as monotherapy for B. fragilis
• Still a cornerstone for: aspiration pneumonia/lung abscess, head and neck infections, gas gangrene (combined with penicillin G)
• Dosage: 600-900 mg IV q6-8h; 300-450 mg PO q6-8h

5. Penicillin G / Ampicillin

• Active against non-B. fragilis anaerobes (Fusobacterium, Peptostreptococcus, Actinomyces, microaerophilic streptococci)
• NOT active against B. fragilis (beta-lactamase producer)
• Added to metronidazole or clindamycin regimens for intracranial, pulmonary, or dental infections to cover microaerophilic streptococci and Actinomyces

6. Cefoxitin (2nd-Generation Cephalosporin)

• Good activity against B. fragilis; used for intra-abdominal and pelvic infections
• Resistance emerging in B. fragilis group - check local susceptibilities

7. Tigecycline

• Broad anaerobic coverage; useful in resistant cases
• Not appropriate for bloodstream infections (low serum levels)

8. Chloramphenicol

• Active against most anaerobes including B. fragilis; used for life-threatening CNS infections when other agents cannot be used
• Use limited by bone marrow toxicity

Antimicrobial Susceptibility Summary (B. fragilis Group)

• Goldman-Cecil Medicine, p. 3078

Site-Specific Treatment Regimens

Head, Neck, and Dental Infections

• Ampicillin-sulbactam IV or clindamycin + penicillin
• Fusobacterium: metronidazole, clindamycin, or amoxicillin-clavulanate
• Lemierre syndrome (Fusobacterium necrophorum): aggressive IV antibiotics; metronidazole or beta-lactam/inhibitor combination

Pulmonary (Aspiration Pneumonia, Lung Abscess, Empyema)

• First-line: Clindamycin (superior to penicillin alone due to B. fragilis/resistant anaerobes)
• Alternative: Ampicillin-sulbactam, or metronidazole + penicillin
• Moxifloxacin is an option; metronidazole monotherapy is NOT adequate (poor activity vs microaerophiles)

Intra-Abdominal Infections

• Mild-moderate: Cefoxitin, cefotetan, or ertapenem; or ampicillin-sulbactam
• Severe/Hospital-acquired: Piperacillin-tazobactam or carbapenem
• Standard combination: Metronidazole + aminoglycoside or fluoroquinolone or anti-gram-negative cephalosporin (e.g., ceftriaxone)
• An anti-gram-negative agent must always be added to metronidazole for abdominal infections

Pelvic Infections

• IV: Clindamycin + gentamicin, or cefoxitin + doxycycline
• Add doxycycline for Chlamydia/Mycoplasma coverage
• Oral step-down: clindamycin, or amoxicillin-clavulanate, or metronidazole

Clostridial Infections (Harrison's Table 159-1)

• Harrison's Principles of Internal Medicine, 22E (2025), p. 1283

Brain Abscess

• Metronidazole + penicillin G (to cover microaerophilic streptococci/Actinomyces) +/- 3rd-generation cephalosporin
• Metronidazole reaches CSF levels equal to serum - makes it ideal here

Necrotizing Fasciitis / Fournier's Gangrene

• Broad empirical coverage: vancomycin or linezolid PLUS one of piperacillin-tazobactam, carbapenem, or ceftriaxone + metronidazole
• Immediate surgical exploration and debridement is the most important intervention

Oral Step-Down Options

• Clindamycin
• Amoxicillin-clavulanate
• Metronidazole (combined with appropriate aerobic coverage)

Duration of Therapy

• Generally longer than aerobic infections
• Minimum 2-3 weeks for most; up to 6-8 weeks for severe infections (e.g., osteomyelitis, brain abscess, actinomycosis) if surgical drainage is inadequate
• Adequate surgical drainage can significantly shorten duration

Key Resistance Concerns (2025)

• B. fragilis group: Increasing resistance to clindamycin, cefoxitin, cefotetan, and moxifloxacin
• Carbapenems and metronidazole remain most reliable for B. fragilis
• Culture and susceptibility testing should guide definitive therapy whenever possible

Recent evidence note: A 2025 meta-analysis (PMID 40154881) found carbapenems superior to metronidazole-combination therapy for Bacteroides spp. infections, reinforcing carbapenem preference for drug-resistant Bacteroides. A 2024 systematic review (PMID 39120079) evaluated metronidazole monotherapy for oral anaerobic infections and confirms its continued role in that setting.

Treatment of Pseudomembranous Colitis (PMC) / Clostridioides difficile Infection (CDI)

Background

General Measures (All Patients)

1. Discontinue the offending antibiotic - first and most important step. Up to 15-23% of mild cases may resolve with this alone. Continuing it lowers cure rates and raises reinfection rates.
2. IV fluid and electrolyte resuscitation - diarrhea causes significant volume depletion.
3. Avoid antiperistaltic agents (loperamide, opioids) in severe disease - may mask symptoms and worsen toxic dilation. (Safe to use with antibiotics in mild-moderate cases.)
4. Contact isolation precautions - C. difficile spores are not killed by alcohol gel; use soap-and-water handwashing and bleach-based disinfection.
5. Test of cure (repeat stool testing) is NOT recommended after treatment - >50% of patients continue to harbor the organism after diarrhea ceases.

Severity Classification

Antibiotic Treatment

First Episode - Non-severe and Severe

• Fidaxomicin is preferred per 2021 IDSA/SHEA guidelines - it equals vancomycin for acute cure (~90% clinical resolution) but significantly reduces recurrence rates due to its narrow spectrum sparing the normal microbiome.
• Vancomycin was shown superior to metronidazole for cure (81% vs 73%, p=0.034) across all CDI severities.
• IV vancomycin is ineffective - does not reach the colonic lumen.
• Metronidazole is no longer first-line; response may be slower (may take >6 days to assess failure).

First Episode - Fulminant CDI

• Goldman-Cecil Medicine, p. 3072; Sabiston Textbook of Surgery, p. 2103; Harrison's Principles of Internal Medicine 22E (2025), p. 1096

Treatment of Recurrent CDI

First Recurrence

Second or Further Recurrences

• Harrison's, p. 1098; Goldman-Cecil Medicine, p. 3072-3073

Surgical Management

• Fulminant CDI with systemic toxicity not responding to antibiotics
• Toxic megacolon
• Colonic perforation
• Progressive deterioration despite maximal medical therapy (escalating WBC, rising lactate, organ failure)

• Total/subtotal abdominal colectomy with end ileostomy - traditional standard; provides survival advantage over continuing antibiotics alone in fulminant disease
• Diverting loop ileostomy + intraoperative colonic lavage + antegrade vancomycin flushes - newer, colon-sparing option with similar results in patients without necrosis or perforation (preserves colon for later reversal)

Summary Algorithm

C. difficile confirmed
        |
        ├── Discontinue offending antibiotic
        |
        ├── Non-severe/Severe
        |       └── Fidaxomicin 200mg BD × 10d (preferred)
        |           OR Vancomycin 125mg QID × 10d
        |
        ├── Fulminant (shock/ileus/megacolon)
        |       └── Vancomycin 500mg QID PO/NG + Metronidazole 500mg IV q8h
        |           ± Vancomycin enema if ileus
        |           + Surgical consultation
        |
        └── Recurrence
                ├── 1st: Fidaxomicin or Vancomycin taper
                ├── 2nd+: FMT (preferred) or Bezlotoxumab
                └── Fulminant recurrence: Surgery

Drugs to Avoid

• Antiperistaltics (loperamide) in severe/fulminant disease
• Proton pump inhibitors - associated with increased CDI risk (avoid if unnecessary)
• Antibiotics highly associated with CDI: quinolones, clindamycin, broad-spectrum cephalosporins - restrict per antimicrobial stewardship

Recent evidence update:

• A 2024 meta-analysis (PMID 39121324) confirmed fidaxomicin significantly reduces CDI recurrence vs vancomycin with similar clinical cure rates.
• The 2024 AGA Clinical Practice Guideline (PMID 38395525) on fecal microbiota-based therapies supports FMT and newer microbiome products (RBX2660/SER-109) for recurrent CDI, reinforcing FMT as the standard for multiply recurrent disease.

Treatment of MRSA (Methicillin-Resistant Staphylococcus aureus)

Core Principles

1. Source control - drain abscesses, remove infected foreign material/devices, eliminate endovascular foci. This is the most common reason for treatment failure when absent.
2. Systemic antimicrobial therapy - guided by susceptibility testing and infection site.

Key Drugs Active Against MRSA

1. Vancomycin (Drug of Choice for Invasive MRSA)

• Dose: 15-20 mg/kg IV q8-12h; total ≤2 g per dose; adjust for renal function
• Monitoring: AUC/MIC-based dosing is preferred; trough-based monitoring also used. Target AUC/MIC ratio ≥400. Trough 15-20 µg/mL for serious infections (bacteremia, endocarditis).
• Important limitation: Strains with vancomycin MIC ≥4 µg/mL (VISA/VRSA) should be considered resistant - vancomycin failure is highly likely. Even MIC 1.5-2 µg/mL ("MIC creep") is concerning.
• Not useful for pulmonary infections - poor lung penetration.
• Not given orally for systemic MRSA (oral vancomycin is not absorbed; only use is for C. difficile colitis).

2. Daptomycin (Major Alternative)

• Dose: 6 mg/kg IV q24h (bacteremia/right-sided endocarditis); 8-10 mg/kg q24h for high-inoculum infections
• Key rule: Do NOT use for MRSA pneumonia - it is inactivated by pulmonary surfactant.
• Enhanced activity: Combination with an anti-staphylococcal β-lactam (e.g., nafcillin, ceftaroline) enhances daptomycin bactericidal activity by reducing bacterial cell-surface charge, even against daptomycin-nonsusceptible isolates.
• Monitor for myopathy (hold statins during therapy).

3. Linezolid (Oxazolidinone)

• Dose: 600 mg PO/IV q12h
• Excellent for: MRSA pneumonia (good lung penetration), skin/soft tissue infections (oral bioavailability ~100%)
• Not first-line for MRSA bacteremia - bacteriostatic, not bactericidal; inferior for endovascular infections.
• Adverse effects: Myelosuppression (thrombocytopenia >2 weeks), serotonin syndrome (MAO-I interaction), peripheral/optic neuropathy with prolonged use.

4. Ceftaroline (5th-Generation Cephalosporin)

• Only β-lactam active against MRSA - binds PBP2a
• Dose: 600 mg IV q12h
• FDA-approved for MRSA skin/soft tissue infections and community-acquired pneumonia
• Used as salvage monotherapy or in combination (with daptomycin or vancomycin) for persistent/refractory MRSA bacteremia
• Enhances daptomycin binding when used in combination

5. Trimethoprim-Sulfamethoxazole (TMP-SMX)

• Dose: 1-2 DS tablets (160/800 mg) PO BID; or 1-2 ampules (5 mg/kg trimethoprim component) IV q8-12h
• Excellent for CA-MRSA skin/soft tissue infections (oral step-down)
• Not reliable for bacteremia or endocarditis due to inoculum effect
• Check local susceptibility - most CA-MRSA strains susceptible; HA-MRSA variable

6. Clindamycin

• Oral: 300-450 mg PO TID
• Active against most CA-MRSA strains; less reliable for hospital-acquired MRSA
• D-zone test required to exclude inducible clindamycin resistance (in erythromycin-resistant isolates)
• Used for mild-moderate SSTI, osteomyelitis (oral step-down)

7. Doxycycline / Tetracyclines

• 100 mg PO BID
• Useful oral option for CA-MRSA SSTI; not for serious invasive infections

8. Newer Agents

Site-Specific Treatment

Skin and Soft Tissue Infections (SSTI)

• Vancomycin 25-30 mg/kg/day IV (divided q8-12h)
• Daptomycin 4-6 mg/kg IV q24h
• Abscesses: Incision and drainage (I&D) is the primary treatment; antibiotic therapy adds benefit even for small abscesses, reducing recurrence and treatment failure. Duration: 5-7 days.
• Cellulitis: 5-12 days depending on severity.
• Necrotizing fasciitis: Emergent surgical debridement + broad-spectrum IV coverage including MRSA.

Bacteremia

• Uncomplicated bacteremia: 14 days (criteria: fever resolves by day 3, blood cultures clear within 1-2 days, removable focus identified, no endocarditis/osteomyelitis/prosthetic devices)
• Complicated bacteremia (metastatic foci, slow resolution): 4-6 weeks
• Endocarditis: 6 weeks

• Daptomycin + ceftaroline combination
• Vancomycin + ceftaroline combination
• TMP-SMX or rifampin + daptomycin
• Linezolid or ceftaroline as single alternative agents

Endocarditis

• Native valve: surgery for heart failure, myocardial abscess, severe valve disease, or vegetation >10 mm
• Prosthetic valve: outcomes worse medically; surgery + reimplantation usually needed

Pneumonia (MRSA HAP/VAP/CAP)

• Vancomycin: Standard choice for IV therapy, but poor lung penetration is a limitation
• Linezolid: Preferred by many experts for MRSA pneumonia (superior lung penetration; some trials show better outcomes)
• Telavancin: IV alternative (lipoglycopeptide)
• Ceftaroline: Active against MRSA; 2023 systematic review (PMID 37852658) supports its use in MRSA pneumonia
• Daptomycin is contraindicated - inactivated by surfactant
• Duration: 7-14 days for uncomplicated; up to 4 weeks if bacteremia or empyema coexist
• Empirical coverage for MRSA pneumonia is indicated in: severe community-acquired pneumonia post-influenza; healthcare-associated/nosocomial pneumonia; known MRSA colonization (positive nasal swab/PCR)

Osteomyelitis and Septic Arthritis

• IV: Vancomycin (preferred for bacteremia, endocarditis) or Daptomycin 6 mg/kg q24h
• Oral step-down (after clinical improvement): TMP-SMX, clindamycin, or linezolid
• Children with hematogenous osteomyelitis: 4-week course usually adequate
• Adults: often more prolonged; chronic osteomyelitis requires surgical debridement
• Septic arthritis: repeated aspiration or arthroscopy to prevent joint damage
• Prosthetic joint infections: rifampin + ciprofloxacin combination (active in biofilm); often requires device removal

CNS Infections (Meningitis, Brain Abscess, Ventriculitis)

• Vancomycin - good CNS penetration; dose 30-60 mg/kg/day IV in divided doses; titrate to CSF trough levels
• Linezolid: alternative (bacteriostatic; reserve for vancomycin failure)
• Rifampin added as combination (enhances bactericidal activity; adjunct only, never monotherapy)

CA-MRSA vs. HA-MRSA: Practical Differences

Summary: Drug of Choice by Site

• Goldman-Cecil Medicine, pp. 3025-3026; Harrison's Principles of Internal Medicine, 22E (2025), pp. 1261-1265

Recent evidence note:

• A 2024 meta-analysis (PMID 38381737) comparing daptomycin vs vancomycin for MRSA bloodstream infections found no significant difference in overall outcomes, supporting both as equivalent first-line agents for bacteremia.
• A 2024 network meta-analysis (PMID 38789000) comparing 6 antibiotics for MRSA found ceftaroline and linezolid among the most effective options, particularly for complex infections.